The EU Pharma Package: Understanding the Impact on Regulatory Exclusivities in the EU.
Join us for our latest seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU.
For any medicine marketed in Europe, a key commercial consideration is the timing of generic or biosimilar market entry. Protection from competition is derived from two principal sources: intellectual property rights (patents and Supplementary Protection Certificates), and regulatory exclusivities. The new EU Pharma Package introduces changes to the regulatory exclusivities that are available.
In this seminar, Dr Andrew Wells (Partner and Head of the HGF Chemistry & Pharmaceutical Group) will explain the proposed reforms and discuss what they mean for both innovator and generic pharmaceutical companies.
We look forward to welcoming you to the seminar.
Please note photography may be taken throughout the event to be used for marketing material, if you would prefer not to be in any photographs please contact us via events@hgf.com
About the hosts:
HGF is one of Europe's leading intellectual property firms, supporting innovative businesses across the life sciences sector, from early-stage spinouts and venture-backed companies to multinational organisations. Through HGF100, we bring together founders, investors and industry leaders to share insights, build connections and support the growth of the life sciences ecosystem.